Differentiation therapy in acute myeloid leukaemia: molecular basis, clinical progress, and future perspectives

1

Acute myeloid leukemia (AML) is characterized by clonal evolution, genetic heterogeneity, and impaired myeloid differentiation.
2

Differentiation therapy has expanded to include various AML subtypes, utilizing agents like IDH and menin inhibitors.
3

Advancements in genomic profiling allow for biomarker-driven patient stratification, enhancing differentiation therapy outcomes.
4

Differentiation therapy aims to restore normal hematopoietic development, contrasting with targeted therapies that inhibit oncogenic signaling.
5

Despite progress, challenges remain in AML treatment, including high relapse rates and the need for reliable prognostic biomarkers.

Frontiers In Medicine

1